This site is intended for healthcare professionals

Fasenra eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE phase IIIb trial.- AstraZeneca.

Read time: 1 mins
Last updated:31st Oct 2020
Published:31st Oct 2020
Condition: Asthma (Eosinophilic)
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest